Enlonstobart

Phase 3Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Enlonstobart is one of 198 small molecule programs targeting Liver Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

197

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerNot yet recruiting

Non-Small Cell Lung CancerNot yet recruiting

Gastric CancerNot yet recruiting

Head and Neck Squamous Cell CarcinomaRecruiting

Cervical CancerNot yet recruiting

Liver CancerPhase 2

Not yet recruiting

Non-Small Cell Lung CancerPhase 3

Not yet recruiting

Gastric CancerPhase 3

Not yet recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Recruiting

Cervical CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

2 2

KN046

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

4 3

Enlonstobart

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 4

Pemetrexed+cisplatin

AstraZeneca

Phase 3

4 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Head and Neck Squamous Cell Carcinoma

NCT07254585

Q1 2029

Phase 2Not yet recruiting

Cervical Cancer

NCT06981858

Phase 1/2Not yet recruiting

Liver Cancer

NCT07282509

Q4 2029

Phase 2Not yet recruiting

Gastric Cancer

NCT06998771

PreclinicalNot yet recruiting

Non-Small Cell Lung Cancer

NCT07662811

Q4 2030

Phase 2Not yet recruiting

Rectal Cancer

NCT07810114

Clinical

Trials by Indication[1]

Gastric Cancer2 trials

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT07332533·490 enrolled

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06998771·153 enrolled

Non-Small Cell Lung Cancer2 trials

SYHX2011 in Combination With Carboplatin and Enlonstobart Versus Nab-Paclitaxel Plus Carboplatin and Tislelizumab as First-Line Therapy for Squamous Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Phase II/III Study

Not yet recruiting·SShanghai Chest Hospital·Preclinical·NCT07662811·396 enrolled

A Phase III, Randomized, Open-Label Study of SYS6010 in Combination With Anti-PD-(L)-1 Monoclonal Antibody Versus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy for Patients With Completely Resected Stage II-IIIB NSCLC Who Have No Actionable Genomic Alterations and Not Achieved a Major Pathological Response.

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3·NCT07672223·570 enrolled

Liver Cancer1 trial

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT07282509·116 enrolled

Cervical Cancer1 trial

A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Not yet recruiting·—·Phase 2·NCT06981858·34 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

An Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SYS6010 Combined With Immunotherapy in the Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2·NCT07254585·110 enrolled

1 more indication

Rectal Cancer1 trial

A Phase II Study of Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer With MSS Status

Not yet recruiting·FFudan University·Phase 2·NCT07810114·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Enlonstobart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enlonstobart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enlonstobart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Enlonstobart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Q4 2029

Q4 2030

Trials by Indication[1]

Gastric Cancer2 trials

Non-Small Cell Lung Cancer2 trials

Liver Cancer1 trial

Cervical Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News